Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph M Connors

Showing results (221-230 of 302) with videos related to

Pageof 31
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2012
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)Leo I Gordon, Fangxin Hong, Richard I Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2007
Revised response criteria for malignant lymphomaBruce D Cheson, Beate Pfistner, Malik E Juweid, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2014
Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphomaDiego Villa, Anupkumar George, John F Seymour, et al.
Blood Advances|July 10, 2019
COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter studyAllison Barraclough, Musa Alzahrani, Marianne Schmidt Ettrup, et al.
Leukemia & Lymphoma|December 8, 2010
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)Christopher P Venner, Joseph M Connors, Heather J Sutherland, et al.
Blood|August 27, 2015
Cell of origin of transformed follicular lymphomaRobert Kridel, Anja Mottok, Pedro Farinha, et al.
The New England Journal of Medicine|July 13, 2022
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's LymphomaStephen M Ansell, John Radford, Joseph M Connors, et al.
Oncoimmunology|August 17, 2017
Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphomaJulie S Nielsen, Andrew R Chang, Darin A Wick, et al.
Cancer|September 25, 2014
Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective studyJorge J Castillo, Mark Bower, Jérémy Brühlmann, et al.
Plos One|September 27, 2013
Sex- and subtype-specific analysis of H2AFX polymorphisms in non-Hodgkin lymphomaKarla L Bretherick, Johanna M Schuetz, Lindsay M Morton, et al.
Pageof 31

Showing results (221-230 of 302) with videos related to

Sort By:
Pageof 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2012
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)Leo I Gordon, Fangxin Hong, Richard I Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2007
Revised response criteria for malignant lymphomaBruce D Cheson, Beate Pfistner, Malik E Juweid, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2014
Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphomaDiego Villa, Anupkumar George, John F Seymour, et al.
Blood Advances|July 10, 2019
COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter studyAllison Barraclough, Musa Alzahrani, Marianne Schmidt Ettrup, et al.
Leukemia & Lymphoma|December 8, 2010
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)Christopher P Venner, Joseph M Connors, Heather J Sutherland, et al.
Blood|August 27, 2015
Cell of origin of transformed follicular lymphomaRobert Kridel, Anja Mottok, Pedro Farinha, et al.
The New England Journal of Medicine|July 13, 2022
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's LymphomaStephen M Ansell, John Radford, Joseph M Connors, et al.
Oncoimmunology|August 17, 2017
Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphomaJulie S Nielsen, Andrew R Chang, Darin A Wick, et al.
Cancer|September 25, 2014
Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective studyJorge J Castillo, Mark Bower, Jérémy Brühlmann, et al.
Plos One|September 27, 2013
Sex- and subtype-specific analysis of H2AFX polymorphisms in non-Hodgkin lymphomaKarla L Bretherick, Johanna M Schuetz, Lindsay M Morton, et al.
Pageof 31